Artificial Intelligence may Aid in Alzheimer's Diagnosis

Machine learning is a type of artificial intelligence that allows computer programs to learn when exposed to new data without being programmed. Now, researchers in The Netherlands have coupled machine learning methods with a special MRI technique that measures the perfusion, or tissue absorption rate, of blood throughout the brain to detect early forms of dementia, such as mild cognitive impairment (MCI), according to a new study published online in the journal Radiology.

"MRI can help with the diagnosis of Alzheimer's disease," said principal investigator Alle Meije Wink, Ph.D., from the VU University Medical Centre in Amsterdam. "However, the early diagnosis of Alzheimer's disease is problematic."

Scientists have long known that Alzheimer's disease is a gradual process and that the brain undergoes functional changes before the structural changes associated with the disease show up on imaging results. Physicians have no definitive way of identifying who has early dementia or which cases of mild cognitive impairment will progress to Alzheimer's disease.

"With standard diagnostic MRI, we can see advanced Alzheimer's disease, such as atrophy of the hippocampus," Dr. Meije Wink said. "But at that point, the brain tissue is gone and there's no way to restore it. It would be helpful to detect and diagnose the disease before it's too late."

For the new study, the researchers applied machine learning methods to special type of MRI called arterial spin labeling (ASL) imaging. ASL MRI is used to create images called perfusion maps, which show how much blood is delivered to various regions of the brain.

The automated machine learning program is taught to recognize patterns in these maps to distinguish among patients with varying levels of cognitive impairment and predict the stage of Alzheimer's disease in new (unseen) cases.

The study included 260 of 311 participants from the Alzheimer Center of the VU University Medical Center dementia cohort who underwent ASL MRI between October 2010 and November 2012.

The study group included 100 patients diagnosed with probable Alzheimer's disease, 60 patients with mild cognitive impairment (MCI) and 100 patients with subjective cognitive decline (SCD), and 26 healthy controls.

SCD and MCI are considered to be early stages of the dementia process and are diagnosed based on the severity of cognitive symptoms, including memory loss and thought- and decision-making problems.

The automated system was able to distinguish effectively among participants with Alzheimer's disease, MCI and SCD. Using classifiers based on the automated machine learning training, the researchers were then able to predict the Alzheimer's diagnosis or progression of single patients with a high degree of accuracy, ranging from 82 percent to 90 percent.

"ASL is a promising alternative functional biomarker for the early diagnosis of Alzheimer's disease," Dr. Meije Wink said.

He added that the application of automated machine learning methods would be useful as a potential screening tool.

"ASL MRI can identify brain changes that appear early in disease process, when there's a window of opportunity for intervention," Dr. Meije Wink said. "If the disease process from SCD to MCI to Alzheimer's disease could be intercepted or slowed, this technique could play a role in screening."

"Application of Machine Learning to Arterial Spin Labeling in Mild Cognitive Impairment and Alzheimer Disease." Collaborating with Dr. Meije Wink were Lyduine E. Collij, B.Sc., Fiona Heeman, B.Sc., Joost P. A. Kuijer, Ph.D., Rik Ossenkoppele, Ph.D., Marije R. Benedictus, Ph.D., Christiane Möller, Ph.D., Sander C. J. Verfaillie, M.Sc., Ernesto J. Sanz-Arigita, Ph.D., Bart N. M. van Berckel, Prof. M.D., Ph.D., Wiesje M. van der Flier, Prof. Ph.D., Philip Scheltens, Prof. M.D., Ph.D., and Frederik Barkhof, Prof. M.D., Ph.D.

Radiology is edited by Herbert Y. Kressel, M.D., Harvard Medical School, Boston, Mass., and owned and published by the Radiological Society of North America, Inc.

RSNA is an association of more than 54,000 radiologists, radiation oncologists, medical physicists and related scientists promoting excellence in patient care and health care delivery through education, research and technologic innovation. The Society is based in Oak Brook, Ill.

Most Popular Now

Open Call HORIZON-JU-IHI-2022-03-05: Dig…

Mental health disorders represent an area of severe unmet public health need. This has been further negatively impacted by the COVID-19 pandemic, with a substantial increase in the number and...

The Future of Medicine is Data

At the 2023 Annual J.P. Morgan Healthcare Conference, Owkin Co-founder and CEO Thomas Clozel, MD will outline how data is the future of medicine - from the development of new...

Brain Area Necessary for Fluid Intellige…

A team led by UCL and UCLH researchers have mapped the parts of the brain that support our ability to solve problems without prior experience - otherwise known as fluid...

Study Surveys Landscape of Apps Built on…

A study led by Regenstrief Institute Research Scientist Titus K. Schleyer, DMD, PhD, is among the first to survey the current landscape of FHIR® apps, providing a snapshot of how...

New Computer Program 'Learns' to Identif…

Genetic mutations cause hundreds of unsolved and untreatable disorders. Among them, DNA mutations in a small percentage of cells, called mosaic mutations, are extremely difficult to detect because they exist...

Applications Open for SpinLab Accelerato…

The start-up accelerator supports entrepreneurial and innovative teams that want to grow sustainably and successfully scale their business model. With a strong hands-on mentality and a lot of passion, the...

Allscripts Announces Corporate Name Chan…

Allscripts Healthcare Solutions, Inc. announced that, effective January 1, 2023, it has changed its name to Veradigm Inc. (NASDAQ: MDRX). Allscripts had been transitioning its solutions to the Veradigm brand...

Bayer to Accelerate Drug Discovery with …

Bayer AG and Google Cloud today announced a collaboration to drive early drug discovery that will apply Google Cloud's Tensor Processing Units (TPUs), which are custom-developed accelerators designed to run...

220M€ Investment in Testing and Experime…

To make the EU the place where AI excellence thrives from the lab to the market, the European Union is setting up world-class Testing and Experimentation Facilities (TEFs) for AI. Together...

Artificial Nerve Cells - Almost Like Bio…

Researchers at Linköping University (LiU), Sweden, have created an artificial organic neuron that closely mimics the characteristics of biological nerve cells. This artificial neuron can stimulate natural nerves, making it...

AI Tool Developed to Predict Risk of Lun…

Lung cancer is the leading cause of cancer death in the United States and around the world. Low-dose chest computed tomography (LDCT) is recommended to screen people between 50 and...

For Shared Decision-Making, Telemedicine…

Telemedicine may be just as effective as in-person visits when it comes to shared decision-making and communication for patients undergoing a first-time surgery consultation, according to a study published as...